Drug intelligence / Profile preview

deoxycholic acid

Development stage: Unknown
Lead developer: BioJeTay
Modality: Small Molecules
Administration: Subcutaneous

Overview

BTM101 is a deoxycholic acid injection developed by BioJeTay for the treatment of moderate to severe submental fat (double chin) in adults. As a synthetic version of a naturally occurring bile acid, it acts as an adipocytolytic agent that physically disrupts the cell membrane of adipocytes upon local injection. This disruption causes the destruction of fat cells, which are then cleared through natural metabolic processes. BTM101 is currently in Phase 3 clinical development in China, positioned as a generic alternative to the reference drug Kybella.

Other names: deoxycholic acid injection

Targets

AE1 (Anion exchange protein 1)Adipocyte cell membrane lipidNTCP (Na+-taurocholate cotransporting polypeptide)

Beyond the preview

Go deeper on deoxycholic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on deoxycholic acid.

Explore the full profile